Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D R Higgins

Showing results (211-220 of 283) with videos related to

Pageof 29
Sort By:
American Journal of Respiratory Cell and Molecular Biology|March 16, 2013
X-linked inhibitor of apoptosis regulates lung fibroblast resistance to Fas-mediated apoptosisIyabode O Ajayi, Thomas H Sisson, Peter D R Higgins, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 30, 2021
A Care Coordination Intervention Improves Symptoms But Not Charges in High-Risk Patients With Inflammatory Bowel DiseaseJeffrey A Berinstein, Shirley A Cohen-Mekelburg, Gillian M Greenberg, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 21, 2018
Efficacy of Induction Therapy With High-Intensity Tofacitinib in 4 Patients With Acute Severe Ulcerative ColitisJeffrey A Berinstein, Calen A Steiner, Randolph E Regal, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 18, 2018
Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative ColitisStephen Hanauer, Remo Panaccione, Silvio Danese, et al.
Alimentary Pharmacology & Therapeutics|April 17, 2014
Letter: biological drugs for inducing remission in ulcerative colitis - authors' replyR W Stidham, T C H Lee, P D R Higgins, et al.
Crohn'S & Colitis 360|March 31, 2023
Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysisRemo Panaccione, Eric B Collins, Gil Y Melmed, et al.
European Journal of Gastroenterology & Hepatology|August 18, 2020
Mapping the relationships between inflammatory bowel disease and comorbid diagnoses to identify disease associationsAkbar K Waljee, Mohamed Noureldin, Jeffrey A Berinstein, et al.
Alimentary Pharmacology & Therapeutics|May 28, 2011
Review article: defining remission in ulcerative colitisS P L Travis, P D R Higgins, T Orchard, et al.
Crohn'S & Colitis 360|February 5, 2024
Association of Bowel Urgency With Quality-of-Life Measures in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From Phase 3 LUCENT-1 (Induction) and LUCENT-2 (Maintenance) StudiesMillie D Long, Stefan Schreiber, Toshifumi Hibi, et al.
Plos One|December 27, 2022
Understanding clinician connections to inform efforts to promote high-quality inflammatory bowel disease careShirley Cohen-Mekelburg, Tony Van, Xianshi Yu, et al.
Pageof 29

Showing results (211-220 of 283) with videos related to

Sort By:
Pageof 29
American Journal of Respiratory Cell and Molecular Biology|March 16, 2013
X-linked inhibitor of apoptosis regulates lung fibroblast resistance to Fas-mediated apoptosisIyabode O Ajayi, Thomas H Sisson, Peter D R Higgins, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 30, 2021
A Care Coordination Intervention Improves Symptoms But Not Charges in High-Risk Patients With Inflammatory Bowel DiseaseJeffrey A Berinstein, Shirley A Cohen-Mekelburg, Gillian M Greenberg, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 21, 2018
Efficacy of Induction Therapy With High-Intensity Tofacitinib in 4 Patients With Acute Severe Ulcerative ColitisJeffrey A Berinstein, Calen A Steiner, Randolph E Regal, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 18, 2018
Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative ColitisStephen Hanauer, Remo Panaccione, Silvio Danese, et al.
Alimentary Pharmacology & Therapeutics|April 17, 2014
Letter: biological drugs for inducing remission in ulcerative colitis - authors' replyR W Stidham, T C H Lee, P D R Higgins, et al.
Crohn'S & Colitis 360|March 31, 2023
Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysisRemo Panaccione, Eric B Collins, Gil Y Melmed, et al.
European Journal of Gastroenterology & Hepatology|August 18, 2020
Mapping the relationships between inflammatory bowel disease and comorbid diagnoses to identify disease associationsAkbar K Waljee, Mohamed Noureldin, Jeffrey A Berinstein, et al.
Alimentary Pharmacology & Therapeutics|May 28, 2011
Review article: defining remission in ulcerative colitisS P L Travis, P D R Higgins, T Orchard, et al.
Crohn'S & Colitis 360|February 5, 2024
Association of Bowel Urgency With Quality-of-Life Measures in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From Phase 3 LUCENT-1 (Induction) and LUCENT-2 (Maintenance) StudiesMillie D Long, Stefan Schreiber, Toshifumi Hibi, et al.
Plos One|December 27, 2022
Understanding clinician connections to inform efforts to promote high-quality inflammatory bowel disease careShirley Cohen-Mekelburg, Tony Van, Xianshi Yu, et al.
Pageof 29